Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Forty Seven. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Forty Seven's earnings available for a low price, and how does
this compare to other companies in the same industry?
Forty Seven's earnings are expected to grow significantly at over 20% yearly.
Unable to determine if Forty Seven is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Forty Seven's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Mark A. McCamish, M.D., Ph.D., has been Chief Executive Officer, Director and President at Forty Seven Inc. since May 1, 2017. Mr. McCamish served as the Global Head of Biopharmaceutical Development at Sandoz International, a Division of Novartis. Mr. McCamish served as Head of Global Development Biopharmaceuticals & Oncology Injectables at Sandoz Inc. Dr. McCamish served as Chief Medical Officer and Senior Vice President of AbbVie Biotherapeutics Inc. (Also known as Facet Biotech Corporation). since December 2008. He served as a Senior Vice President and Chief Medical officer of PDL BioPharma Inc., from February 21, 2007 to December 2008. He has over 25 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish served as Vice President of Clinical Development at Perlegen Sciences Inc. from August 2003 to February 2007 and served as its Chief Medical Officer from September 2003 to February 2007. From January 1998 to September 2003, he served at Amgen, Inc., as a Global Development Leader and was responsible for the clinical development of Amgen's Aranesp® product in new indications. He serves as a Director of Trigemina, Inc. He served as Medical Director of Abbott Laboratories. From 1990 to 1997, he served as a Director at Abbott Laboratories. Dr. McCamish also served as a Member of Amgen's International Clinical Oversight Group responsible for approval of all clinical research protocols, clinical study reports and FDA/Regulatory submissions. Dr. McCamish served positions as a professor of Surgery at Michigan State University from 1980-1983, Internal Medicine at the University of California at Davis from 1987-1990 and Endocrinology at The Ohio State University from 1990-1997. He is a Board Certified in Internal Medicine and Nutrition & Metabolism. Dr. McCamish holds a B.S. in Physical Education and an M.S. in Ergonomics from the University of California at Santa Barbara, a Ph.D. in Human Nutrition from The Pennsylvania State University and an M.D. from the University of California at Los Angeles.
Insufficient data for Mark to compare compensation growth.
Mark's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Forty Seven management team is about average.
Chief Business Officer
Chief Medical Officer
Founder & VP of Clinical Development
Founder and VP of Research & Early Development
Chief Financial Officer
Senior Vice President of Planning & Operations
Chief Patent Counsel
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Forty Seven board of directors is less than 3 years, this suggests a new board.
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.